Literature DB >> 8141564

Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes.

C Alfieri1, A C Allison, E Kieff.   

Abstract

The effect of mycophenolic acid (MPA) on the growth of Epstein-Barr virus (EBV)-transformed B cells and on EBV lytic-cycle gene expression was investigated. MPA inhibited the proliferation of newly infected or established EBV-transformed B-cell lines but was not able to block cell growth transformation or the viral lytic cycle. These results suggest that MPA might reduce transformed-cell proliferation in transplant patients and possibly decrease the risk of development of EBV-related lymphoproliferative disorders.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8141564      PMCID： PMC284407          DOI： 10.1128/AAC.38.1.126

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Analysis of the transformation of human lymphocytes by Epstein-Barr virus. I. Sequential occurrence from the virus-determined nuclear antigen synthesis, to blastogenesis, to DNA synthesis.

Authors:  K Takada; T Osato
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

2.  Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents.

Authors:  E M Eugui; A Mirkovich; A C Allison
Journal:  Transplant Proc       Date:  1991-04       Impact factor: 1.066

3.  In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443.

Authors:  A C Allison; S J Almquist; C D Muller; E M Eugui
Journal:  Transplant Proc       Date:  1991-04       Impact factor: 1.066

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation.

Authors:  C E Freise; M Hebert; R W Osorio; B Nikolai; J R Lake; R S Kauffman; N L Ascher; J P Roberts
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

6.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

7.  Infection of human B lymphocytes with high multiplicities of Epstein-Barr virus: kinetics of EBNA expression, cellular DNA synthesis, and mitosis.

Authors:  J Robinson; D Smith
Journal:  Virology       Date:  1981-03       Impact factor: 3.616

Review 8.  The role of de novo purine synthesis in lymphocyte transformation.

Authors:  A C Allison; T Hovi; R W Watts; A D Webster
Journal:  Ciba Found Symp       Date:  1977

9.  RS-61443--a phase I clinical trial and pilot rescue study.

Authors:  H W Sollinger; M H Deierhoi; F O Belzer; A G Diethelm; R S Kauffman
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

10.  Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion.

Authors:  E M Eugui; S J Almquist; C D Muller; A C Allison
Journal:  Scand J Immunol       Date:  1991-02       Impact factor: 3.487
View more
  2 in total

1.  EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.

Authors:  Daniel Portal; Bo Zhao; Michael A Calderwood; Thomas Sommermann; Eric Johannsen; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  Virtual high-throughput screening identifies mycophenolic acid as a novel RNA capping inhibitor.

Authors:  Maude Tremblay-Létourneau; Simon Despins; Isabelle Bougie; Martin Bisaillon
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.